Summary & Overview
CPT 55877: Prostate Tumor Ablation with Irreversible Electroporation
CPT code 55877 represents percutaneous irreversible electroporation (IRE) ablation of one or more prostate tumors, a minimally invasive, image-guided procedure that destroys tumor cells using short, high-voltage electrical pulses rather than thermal or cryogenic energy. Nationally, the code matters as IRE offers a focal prostate cancer treatment option with distinct technical characteristics and billing considerations that payers and providers evaluate for coverage, utilization, and care pathways.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical service and site-of-service context, payer coverage patterns and benchmark considerations, coding and billing nuances tied to the procedure description, and related policy updates affecting reimbursement and prior authorization trends. The publication also summarizes utilization benchmarks where available and highlights common documentation elements and imaging guidance inclusion inherent to the service.
This national review is intended for payers, provider billing teams, and health policy stakeholders seeking a clear, actionable synopsis of CPT code 55877, its clinical context, and the payer landscape influencing access and billing for prostate IRE ablation.
Billing Code Overview
CPT code 55877 describes ablation of one or more prostate tumors using irreversible electroporation (IRE). The procedure is a minimally invasive, percutaneous tumor ablation in which a probe is inserted through the skin into the prostate. The probe delivers very short, high-voltage electrical pulses that permanently disrupt tumor cell membranes, causing cell death without heat or freezing. Imaging guidance is included as part of the service.
Service type: Percutaneous tumor ablation (irreversible electroporation)
Typical site of service: Outpatient ambulatory surgery center or hospital outpatient setting (percutaneous image-guided prostate tumor ablation)
Clinical & Coding Specifications
Clinical Context
A typical patient is a 65-year-old man with localized, biopsy-proven prostate carcinoma confined to the gland who elects focal tumor ablation. He presents after multiparametric MRI and targeted biopsy confirm one or more discrete tumor foci suitable for a percutaneous approach. Pre-procedure assessment includes medical clearance, coagulation review, and review of prior imaging (MRI/ultrasound). On the day of service, the patient receives conscious sedation or general anesthesia in an outpatient procedural suite or ambulatory surgery center. Under transrectal or transperineal ultrasound and/or CT/MRI fusion guidance, the interventional urology or interventional radiology team inserts one or more probes percutaneously into the prostate tumor(s). The device delivers irreversible electroporation (IRE) electrical pulses to ablate tumor cells while preserving surrounding structures. Intra-procedural imaging guidance and neurovascular bundle assessment are performed. Post-procedure, the patient is observed for urinary retention, hematuria, and pain, receives discharge instructions, and returns for follow-up PSA monitoring and imaging as indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure | Use when a separate E/M visit for pre- or post-procedure management is medically necessary and documented on the same day as the IRE procedure. |
| Distinct procedural service | Use when another procedure performed on the same day is separate and distinct from the IRE ablation and documentation supports separate anatomic site or separate session.